SEC Form 4

FORM 4

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person[*] Downey Gregory	2. Issuer Name **and** Ticker or Trading Symbol Lexaria Bioscience Corp. [LEXX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
(Last) (First) (Middle) 100 - 740 MCCURDY ROAD	3. Date of Earliest Transaction (Month/Day/Year) 10/14/2022	Director ☐ 10% Owner ☐ X Officer (give title below) Other (specify below) ☐ Chief Financial Officer
(Street) KELOWNA A1 V1X 2P7	4. If Amendment, Date of Original Filed (Month/Day/Year) 10/18/2022	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (State) (Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
common shares								1,833	D	
common shares	10/14/2022		P[(1)]		121	A	$2.09	1,954	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options	$5.04							04/15/2021	04/15/2026	Common Shares	4,000		4,000	D	
Stock Options	$5.04							04/15/2022	04/15/2026	Common Shares	4,000		8,000	D	
Stock Options	$5.04							04/15/2023	04/15/2026	Common Shares	4,000		12,000	D	
Stock Options	$5.31							04/26/2022	04/26/2026	Common Shares	5,000		17,000	D	
Stock Options	$7.08							06/08/2021	06/08/2026	Common Shares	8,000		25,000	D	
Stock Options	$6.23							09/01/2021	09/01/2026	Common Shares	10,000		35,000	D	
Stock Options	$2.91							08/29/2022	08/29/2027	Common Shares	11,000		46,000	D	

Explanation of Responses:

1. This Form 4A is being filed to correct the transaction code for the open market purchase made by Mr. Downey as originally notated as a grant or award in the Form 4 filed on October 18, 2022.

/Gregory Downey/	10/18/2022
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.